Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$3B
P/E
N/A
Revenue Growth
0.0%
Gross Margin
N/A
ROE
N/A
About Intellia Therapeutics
As a small-cap biotech company trading on the NASDAQ, Intellia Therapeutics has established itself, with direct, concentrated exposure to the biotech and genomics theme. In-vivo CRISPR gene-editing leader with promising liver disease candidates. With a $3B market capitalization and no current profitability, the company demonstrates top-line contraction at 0% year-over-year.
Expert Coverage
Unlock Full NTLA Analysis
Expert analysis and coverage for Intellia Therapeutics
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-07-03
More in Biotech & Genomics
BEAM
Beam Therapeutics
90
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%RXRX
Recursion Pharmaceuticals
88
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%